*The following content is generated by AI and is for reference only.
Overview
Abiraterone acetate (CAS 154229-18-2, C23H30NO2) is a potent inhibitor of CYP17A1 used in oncology. It is synthesized via selective oxidation and esterification to block androgen biosynthesis.
Application
- Oncology Manufacturing: Production of oral tablets for metastatic castration-resistant prostate cancer.
- Clinical Research: Active pharmaceutical ingredient (API) supply for Phase III trials evaluating combination therapies with prednisone.
Precautions
Requires strict storage below 25°C in dry conditions. Clinical use mandates monitoring for hepatotoxicity, hypertension, and hypokalemia due to mineralocorticoid excess.